Guilherme Rabinowits

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/374828/publications.pdf

Version: 2024-02-01

32 papers

2,100 citations

567281 15 h-index 434195 31 g-index

33 all docs 33 docs citations

33 times ranked 4137 citing authors

#	Article	IF	CITATIONS
1	PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. New England Journal of Medicine, 2018, 379, 341-351.	27.0	997
2	<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discovery, 2018, 8, 196-215.	9.4	392
3	Merkel Cell Polyomavirus Exhibits Dominant Control of the Tumor Genome and Transcriptome in Virus-Associated Merkel Cell Carcinoma. MBio, 2017, 8, .	4.1	100
4	Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <i>TP53</i> . Clinical Cancer Research, 2021, 27, 5236-5247.	7.0	74
5	Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. British Journal of Cancer, 2016, 115, 252-260.	6.4	66
6	Merkel Cell Carcinoma: A Population Analysis on Survival. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1247-1257.	4.9	57
7	The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. Oncologist, 2017, 22, 343-350.	3.7	57
8	Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2016, 22, 2939-2949.	7.0	51
9	Comparative Analysis of MicroRNA Expression among Benign and Malignant Tongue Tissue and Plasma of Patients with Tongue Cancer. Frontiers in Oncology, 2017, 7, 191.	2.8	42
10	Cabozantinib in Patients with Advanced Merkel Cell Carcinoma. Oncologist, 2018, 23, 814-821.	3.7	30
11	CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma. Future Oncology, 2020, 16, 11-19.	2.4	27
12	Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2018, 102, 137-145.	0.8	24
13	Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma. Cancer Biomarkers, 2017, 19, 129-136.	1.7	22
14	Successful Management of a Patient with Malignant Thyroid Teratoma. Thyroid, 2017, 27, 125-128.	4.5	21
15	Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma. European Journal of Cancer, 2019, 113, 1-9.	2.8	19
16	A case of Graves' ophthalmopathy associated with pembrolizumab (Keytruda) therapy. Journal of AAPOS, 2018, 22, 310-312.	0.3	15
17	Systemic Therapy for Merkel Cell Carcinoma: What's on the Horizon?. Cancers, 2014, 6, 1180-1194.	3.7	14
18	Is this the end of cytotoxic chemotherapy in Merkel cell carcinoma?. OncoTargets and Therapy, 2017, Volume 10, 4803-4807.	2.0	14

#	Article	IF	CITATIONS
19	Merkel Cell Carcinoma Presenting as Subcutaneous Breast Masses: An Uncommon Presentation of a Rare Neuroendocrine Neoplasm. Breast Journal, 2016, 22, 113-115.	1.0	12
20	Health-related quality of life (HRQL) in patients with advanced cutaneous squamous cell carcinoma (CSCC) treated with cemiplimab: Post hoc exploratory analyses of a phase II clinical trial Journal of Clinical Oncology, 2020, 38, 10033-10033.	1.6	11
21	Optimizing Tobacco Cessation Resource Awareness Among Patients and Providers. Journal of Oncology Practice, 2016, 12, e77-e82.	2.5	9
22	IMRTâ€based treatment of unknown primary malignancy of the head and neck: Outcomes and improved toxicity with decreased mucosal dose and larynx sparing. Head and Neck, 2019, 41, 959-966.	2.0	8
23	Human papillomavirus and induction chemotherapy versus concurrent chemoradiotherapy in locally advanced oropharyngeal cancer: The Dana Farber Experience. Head and Neck, 2016, 38, E1618-24.	2.0	7
24	Patient-oriented toxicity endpoints after head and neck reirradiation with intensity modulated radiation therapy. Oral Oncology, 2017, 73, 160-165.	1.5	7
25	Checkpoint inhibition in immunosuppressed or immunocompromised patients with advanced cutaneous squamous cell carcinoma (CSCC): Data from prospective CemiplimAb-rwlc Survivorship and Epidemiology (C.A.S.E.) study Journal of Clinical Oncology, 2021, 39, 9547-9547.	1.6	7
26	Evidence-Based Consensus Recommendations for the Evolving Treatment of Patients with High-Risk and Advanced Cutaneous Squamous Cell Carcinoma. JID Innovations, 2021, 1, 100045.	2.4	5
27	Association of Programmed Death 1 Protein Ligand (PD-L1) Expression With Prognosis in Merkel Cell Carcinoma. Frontiers in Medicine, 2020, 7, 198.	2.6	4
28	Update on the Biology and Clinical Management of Merkel Cell Carcinoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e405-e410.	3.8	3
29	Optimizing smoking cessation resource awareness among patients and providers Journal of Clinical Oncology, 2014, 32, 85-85.	1.6	2
30	Analysis of immune infiltrates in a genomically characterized clinical cohort of head and neck squamous cell carcinoma (HNSCC) patients (pts) Journal of Clinical Oncology, 2016, 34, 6052-6052.	1.6	1
31	Consider Surgery, but Not in This Case. International Journal of Radiation Oncology Biology Physics, 2018, 100, 16.	0.8	0
32	Differences between gene mutation profile and outcome of Merkel cell polyomavirus (MCPyV) positive and negative Merkel cell carcinoma (MCC) Journal of Clinical Oncology, 2016, 34, 9577-9577.	1.6	0